Prostate cancer has the second highest incidence among cancers in men worldwide and is the second leading cause of cancer deaths of men in the United States. Although androgen deprivation can initially lead to remission, the disease often progresses to castration-resistant prostate cancer (CRPC), which is still reliant on androgen receptor (AR) signaling and is associated with a poor prognosis. Some success against CRPC has been achieved by drugs that target AR signaling, but secondary resistance invariably emerges, and new therapies are urgently needed. Recently, inhibitors of bromodomain and extraterminal (BET) family proteins have shown growth-inhibitory activity in preclinical models of CRPC. Here, we demonstrate that ARV-771, a small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition. Unlike BET inhibitors, ARV-771 results in suppression of both AR signaling and AR levels and leads to tumor regression in a CRPC mouse xenograft model. This study is, to our knowledge, the first to demonstrate efficacy with a small-molecule BET degrader in a solid-tumor malignancy and potentially represents an important therapeutic advance in the treatment of CRPC.
. Androgen ablation by surgical or chemical castration brings about remission of localized PCa in the great majority of early-stage patients (1) (2) (3) . However, the disease eventually progresses to a more aggressive form known as castration-resistant prostate cancer (CRPC), which presents clinically as an increase in serum prostate-specific antigen (PSA) while circulating testosterone remains at castration levels (4) . Although the etiology of disease progression can be complex, it is thought that high AR expression resensitizes tumor cells to low levels of adrenal androgens (5) . Although CRPC is now known to be reliant on androgen signaling, traditional endocrine therapies are ineffective against it (6) . Until recently, the only treatments approved by the Food and Drug Administration (FDA) for metastatic CRPC were microtubule-disrupting taxanes such as docetaxel and cabazitaxel, which provide only a modest survival benefit (7) . Second-generation AR-axis inhibitors such as abiraterone acetate and enzalutamide have now been granted FDA approval against metastatic CRPC. Although both drugs result in improved survival among patients, approximately a third of patients demonstrate no serum PSA response to these drugs (8) (9) (10) . The rest acquire secondary resistance, marked by a restoration of AR signaling and serum PSA levels (11) . This reactivation of AR signaling is partly mediated by constitutively active AR splice variants that lack the ligand-binding domain (12) (13) (14) . Interestingly, a growing body of literature suggests that these truncated AR variants require functional full-length AR (FL-AR) to mediate drug resistance. Specifically, the AR variants AR-V7 and AR v567es have been shown to heterodimerize with FL-AR, enable its nuclear localization, and facilitate the expression of canonical AR target genes (15, 16) . Similarly, simultaneous antisense-oligo-mediated down-regulation of AR-V7 and FL-AR offers no additional benefit over FL-AR down-regulation alone in enzalutamide-resistant LnCaP-derived xenografts (17) . These data taken together argue strongly for the development of new strategies to tackle AR signaling in CRPC (18) .
Inhibition of the bromodomain and extra-terminal (BET) family of proteins has been proposed as an epigenetic approach in tackling CRPC. BET inhibitors result in growth inhibition in tumor models of CRPC (19) (20) (21) . In addition, BET proteins 2, 3, and 4 (BRD2/3/4) bind AR directly, in a manner that is disrupted by BET inhibitors (20) . This disruption results in abrogation of AR-mediated transcription, thus making BET proteins an attractive target in CRPC. Interestingly, although BET inhibitors attenuate AR transcriptional activity, their effect on AR protein levels is controversial. Two recent studies claim that BET inhibition does not alter FL-AR levels (19, 20) . However, one report shows attenuation of both FL-AR and AR-V7 levels (22) . We and others have recently developed small-molecule degraders of BET proteins (23) (24) (25) . These heterobifunctional molecules, known as "proteolysis targeting chimeras" (PROTACs), contain a ligand for a target protein of interest connected via a linker to a ligand for an E3 ubiquitin ligase (26, 27) . Thereby, treatment of cells with a PROTAC results in the formation of a trimeric complex that allows ubiquitination and subsequent degradation of the target protein via the proteasome (Fig. S1 ) (28) . We previously demonstrated that a BET PROTAC that recruits the E3 ligase cereblon (CRBN) results in potent BET degradation and sustained inhibition of downstream signaling in Burkitt lymphoma cell lines
Significance
We describe the development of a small molecule that mediates the degradation of bromodomain and extra-terminal (BET) proteins and its application in the treatment of castrationresistant prostate cancer (CRPC). Few therapeutic options exist to treat CRPC, especially CRPC tumors expressing constitutively active androgen receptor (AR) splice variants that lack the ligand-binding domain and can effect androgen-independent transactivation of target genes. Importantly, we demonstrate that targeted degradation of BET proteins using proteolysis-targeting chimera (PROTAC) technology causes cell death in cultured prostate cancer cells and results in tumor growth inhibition or regression in mouse models of CRPC, including models that express high levels of AR splice variant 7. Our work thus contains a significant potential therapeutic advance in the treatment of this cancer. (23) . A second group developed CRBN-based BET PROTACs in parallel and demonstrated tumor growth inhibition (TGI) with intraperitoneal delivery in an acute myeloid leukemia (AML) subcutaneous xenograft mouse model (25) .
In this study, we demonstrate that ARV-771, a von HippelLandau (VHL) E3 ligase-based BET PROTAC, is highly active against cellular models of CRPC. ARV-771 in these cells results in rapid BET protein degradation with DC 50 (the drug concentration that results in 50% protein degradation) values <1 nM. Interestingly, ARV-771-mediated BET degradation leads to the decrease of both FL-AR and AR-V7 at the transcript level. In contrast, treatment of CRPC cells with BET inhibitors leads to the suppression of AR-V7 but not of FL-AR levels. Moreover, ARV-771 causes significantly greater apoptotic cell death than a BET inhibitor. Finally, subcutaneous delivery of ARV-771 is efficacious in two different mouse models of CRPC and results in tumor regression in enzalutamide-resistant 22Rv1 xenografts. Thus, this study validates BET protein degradation as a promising clinical strategy against metastatic CRPC and demonstrates the feasibility of treating solid-tumor malignancies with smallmolecule-mediated protein degradation using PROTACs.
Results ARV-771 Is a Potent BET Degrader in Cellular Models of CRPC. To meet our twin goals of developing a highly potent BET protein degrader that also possesses a pharmacokinetic (PK) profile favorable for in vivo testing, we used the triazolo-diazepine acetamide BET-binding moiety derived from BET inhibitors in clinical development (29) . The BET-binding ligand was conjugated via a connecting linker to a recently described HIF-1α-derived (R)-hydroxyproline containing a VHL E3 ligase-binding ligand (30) to generate BET PROTACs. Lead molecules generated by varying linker length and composition were optimized for drug-like properties to obtain PROTACs suitable for in vivo studies. To this end, the BET PROTAC ARV-771 was developed. We also designed ARV-766, a diastereomer of ARV-771 with the opposite configuration at the hydroxyproline, which has no affinity for VHL, as a negative control for BET degradation (Fig. 1A) . ARV-771 potently degrades BRD2/3/4 in 22Rv1 cells with a DC 50 < 5 nM (Fig. 1B) . We confirmed equally potent activity in the VCaP and LnCaP95 CRPC cell lines (Fig. 1B) . Next, we ensured loss of BET function with ARV-771 by measuring levels of the c-MYC protein, a downstream effector of BET proteins. Indeed, treatment with ARV-771 resulted in depletion of c-MYC with an IC 50 <1 nM ( Fig. 1 C and D) . In the same assay, the BET inhibitors JQ-1 and OTX015 were respectively approximately 10-and 100-fold less potent than ARV-771. Similarly, dBET1, a CRBN-based BET degrader reported in the literature, was ∼500-fold weaker than ARV-771. ARV-825 (23), a CRBN-based PROTAC with suboptimal PK, was as potent as ARV-771 in suppressing c-MYC. We determined the binding affinity of ARV-771 and the diastereomer ARV-766 for BET bromodomains to be comparable to that of K d of JQ-1 as reported in the literature (31) (Fig. S2A) . However, ARV-766 demonstrated only marginal suppression of c-MYC, suggesting that BET PROTACs have lower cellular permeability than JQ-1 and that the remarkable potency of ARV-771 is most likely caused by the "catalytic" nature of its cellular activity (26) . The c-MYC suppression was indeed at the mRNA level, as determined by quantitative PCR (qPCR) (Fig. 1D) . Finally, we confirmed the VHL and proteasome dependence of ARV-771 activity by blocking it with an excess of the VHL ligand ARV-056 (Fig. S2B ) or with the proteasome inhibitor carfilzomib (Fig. 1E) . Interestingly, treatment with ARV-771 resulted in the appearance of a high-molecular-weight band in the BRD4 immunoblot, which is notably stronger in the presence of carfilzomib. Our efforts to characterize this band as ubiquitinated BRD4 proved inconclusive (Fig. S2C) , and we hypothesize that it could represent a preproteolytic aggregated BRD4 species. The identity of the BRD4 bands was confirmed using RNAi (Fig. S2D ).
ARV-771 Treatment of CRPC Cells Results in Apoptosis.
We next examined the effect of ARV-771 on cell proliferation. In the three or the proteasome inhibitor carfilzomib (1 μM). The Western blot is representative of two independent experiments (n = 2). All data represent mean values ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). P values were determined using GraphPad Prism using an unpaired parametric t test with Welch's correction.
cell lines tested (22Rv1, VCaP, and LnCaP95), ARV-771 was 10-to 500-fold more potent than JQ-1 or OTX015. Under our test conditions, both the diastereomer ARV-766 and enzalutamide had minimal effect on the proliferation of any of these cell lines, and the VHL ligand ARV-056 was completely inactive (Fig. 2 A  and C) . Notably, ARV-771 treatment had a pronounced effect on cell morphology consistent with apoptosis ( Fig. S2E ), which we corroborated by demonstrating that ARV-771 treatment was associated with significant caspase activation ( Fig. 2 B and D) . Finally, we confirmed the rapid induction of apoptosis with ARV-771 by demonstrating significant poly (ADP-ribose) polymerase (PARP) cleavage in 22Rv1 cells 16 h after PROTAC treatment (Fig. 2E) . Under the same conditions, ARV-766 and the BET inhibitor OTX015 failed to induce any detectable PARP cleavage.
ARV-771 Suppresses FL-AR and AR-V7 Expression. Although BET inhibitor activity against CRPC cells arises from mechanisms such as c-MYC suppression as well as from the inhibition of ARdriven transcription (19, 20) , we hypothesized that BET depletion with ARV-771 may result in additional cellular effects. Interestingly, ARV-771, but not JQ-1 or OTX015, significantly lowered AR protein levels in VCaP cells as measured by ELISA (Fig. 3A) and immunoblotting (Fig. 3B) . Although only FL-AR was detectable at the protein level in VCaP cells, expression of the mRNA encoding both FL-AR and the AR-V7 could be measured readily. AR-V7 is the best studied of the transcriptionally active AR splice variants detected in the clinic and has been hypothesized to play a role in acquired resistance to enzalutamide and abiraterone (6, 11, 12, (32) (33) (34) . We observed downregulation of both FL-AR and AR-V7 mRNA upon treatment with 10 nM ARV-771 in VCaP cells (Fig. 3C) . Although the BET inhibitor JQ-1 lowered AR-V7 levels in this assay, it had no effect on FL-AR. Similar results were obtained in LnCaP95 cells (Fig. S3A) . In 22Rv1 cells, however, the levels of FL-AR showed more complex regulation in response to ARV-771, whereas AR-V7 levels were attenuated (Fig. S3B) . As expected, ARV-766 showed no effect on either FL-AR or AR-V7 levels. The time course of AR downregulation and BRD4 degradation also was established in VCaP cells. Interestingly, although the loss of BRD4 was complete by 6 h following ARV-771 treatment, levels of FL-AR took longer to attenuate (Fig. S3C) . Treatment with the synthetic androgen R1881 down-regulated both transcripts, and enzalutamide had the opposite effect, as has been reported previously (35) (36) (37) . Finally, we showed that ARV-771 has an antiandrogenic effect on a number of AR-regulated genes in VCaP cells (Fig. 3D) . In addition, we carried out an RNA-sequencing experiment in 22Rv1 cells in which we analyzed changes in gene expression upon treatment with either 30 nM ARV-771 or 500 nM OTX015 (Datasets S1 and S2). Interestingly, although AR signaling was not identified by an unbiased bioinformatics analysis as one of the top five networks targeted by ARV-771 (Dataset S3), the levels of a number of AR-regulated genes (ELL2, PMEPA1, STEAP1, FAM105A, ATAD2, ENDOD1, and ZNF189) were found to be attenuated by >50% in this experiment. Similarly, immunoblotting for ERG, which also is regulated by AR in VCaP cells, revealed that the induction of this gene by the synthetic androgen R1881 could be blocked by ARV-771 pretreatment, providing further evidence that BET degradation with the PROTAC blocks AR signaling (Fig. 3E) . All data represent mean values ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). P values were determined using GraphPad Prism using an unpaired t test with a false-discovery rate of 1%. (E) ERG induction by a 16-h treatment with R1881 in VCaP cells is blocked by a 1-h ARV-771 pretreatment. All data represent mean values ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). P values were determined using GraphPad Prism using an unpaired parametric t test with Welch's correction.
ARV-771 Induces Degradation in Vivo. We next established that ARV-771 possesses physicochemical attributes that are favorable for in vivo experiments (Table S1 ). Consistent with these data, the PK profile of ARV-771 revealed that a single subcutaneous administration of a 10-mg/kg dose resulted in plasma drug levels significantly above the predicted efficacious concentration [c-MYC IC 90 = 100 nM with 50% (vol/vol) mouse serum] (Table  S1 ) for 8-12 h (Fig. S4A) . Importantly, treatment of noncastrated male Nu/Nu mice bearing AR-V7 + 22Rv1 tumor xenografts with daily subcutaneous injections of ARV-771 at 10 mg/kg for 3 d resulted in 37% and 76% down-regulation of BRD4 and c-MYC levels, respectively, in tumor tissue (Fig. 4A) . Separately, 2 wk of daily dosing resulted in a dose-dependent suppression of BRD4 and c-MYC in tumors with 10 mg/kg >80% knockdown of both at 8 h following the last 10-mg/kg dose. (Fig. 4 B and C and Fig.  S4B ). The corresponding 8-h ARV-771 plasma concentration of 1,200 ± 230 nM in these mice (Table S2 ) was significantly higher than its c-MYC IC 90 in mouse serum, consistent with the robust BRD4 and c-MYC knockdown that was observed. Interestingly, administration of c-MYC 50 mg/kg OTX015 by oral gavage resulted in c-MYC down-regulation but also in an accumulation of BRD4 protein (Fig. 4 B and C) . Finally, we also observed a marked down-regulation in levels of AR-V7 in the 22Rv1 tumors after ARV-771 treatment ( Fig. 4D and Fig. S4C ).
ARV-771 Induces Regression in 22Rv1 Tumor
Xenografts. Next, we tested the hypothesis that BET degradation with ARV-771 should result in improved efficacy as compared with BET inhibition in the context of an animal model of CRPC. For this purpose, we first examined the 22Rv1 tumor xenograft model, in which the BET inhibitor OTX015 has been reported to result in TGI (21) . Daily subcutaneous administration of ARV-771 in noncastrated male Nu/Nu mice bearing 22Rv1 tumors resulted in a dose-dependent decrease in average tumor size as compared with vehicle administration (Fig. 5 A and B) . Strikingly, the 30-mg/kg dose of ARV-771 induced tumor regression, with 2 of 10 mice being devoid of any palpable tumor mass after treatment. No significant difference in tumor size was seen with treatment with the diastereomer ARV-766 as compared with vehicle control, validating the applicability of the PROTAC mechanism in vivo. Interestingly, OTX015 resulted in 80% TGI in our hands, outperforming the reported results (21) but still representing progressive disease. The TGI achieved with OTX015 probably can be explained by its PK profile, which reveals much higher plasma concentrations of the molecule than of ARV-771 (Fig.  S4A) . Docetaxel treatment, representing the current chemotherapeutic approach in drug-resistant metastatic CRPC, resulted in TGI similar to that achieved with OTX015, proving that BET degradation represents an improvement over the current clinical treatment regimen in cases of enzalutamide-or abirateroneresistant PCa. Crucially, no treatment resulted in a significant loss in body weight, providing evidence that the observed tumor shrinkage was not a product of systemic in vivo toxicity (Fig.  S5A) . Interestingly, we did observe noticeable skin discoloration, suggesting an overall deterioration of skin health, originating at the injection site in the mice receiving chronic ARV-771 dosing but not in those receiving the inactive epimer ARV-766. BRD4 depletion in the skin recently has been shown to result in epithelial hyperplasia, along with follicular dysplasia and subsequent alopecia (38) . However, these severe effects have been shown to be rapidly reversible, and in our experiments the appearance of the skin returned to normal after a 2-to 3-d dosing holiday.
Next, we confirmed that ARV-771 efficacy in 22Rv1 tumor xenografts was not an artifact of cellular lineage. Specifically, we chose the VCaP tumor model, which represents the clinical setting of AR overexpression following androgen-deprivation therapy. Because the CB17 SCID mice bearing VCaP xenografts did not tolerate daily dosing of either ARV-771 or OTX015, we explored intermittent dosing in this experiment. Noncastrated male CB17 SCID mice bearing VCaP tumor xenografts were treated with two intermittent dosing schedules of ARV-771, every 3 d (Q3D) or 3 d on/4 d off, for a total of 16 d, during which the vehicle arm underwent a quadrupling of tumor size (Fig. 5 C and D) . Both dosing schedules resulted in an identical 60% TGI over this time course without significant loss in body weight in either arm (Fig. S5B) . In comparison, enzalutamide had a marginal impact on tumor growth. Although we observed no alopecia with ARV-771 dosing in the CB17 SCID mice, the lack of tolerance for daily dosing does suggest potentially significant toxic effects. With chronic intermittent dosing in our experiment, toxicity presented primarily as hunching of the spine, along with lethargy and decreased mobility in PROTAC-treated mice.
BRD4 levels in tumor samples from the Q3D arm were found to be down-regulated by an average of 57% compared with vehicle, with an 88% drop in corresponding c-MYC levels ( Fig. 5E and Fig. S5C ). Plasma PK analysis of the Q3D arm revealed that the lack of BRD4 and c-MYC suppression in animal no. 3 ( Fig.  5E ) was explained by the corresponding low levels of the drug in circulation (Table S3) , further consolidating the PK/pharmacodynamic relationship with ARV-771. Crucially, ARV-771 lowered circulating PSA, a surrogate for PCa tumor burden in the clinic, by 60% or 80% by ELISA, depending on the dosing schedule (Fig. 5F) . Surprisingly, although enzalutamide had little impact on tumor growth, it resulted in a 40% reduction in PSA serum levels. Finally, we confirmed our findings of BRD4 and c-MYC suppression with immunohistochemical analysis of tumor samples collected from the vehicle and ARV-771 Q3D cohorts (Fig. 5G) .
Discussion
Despite recent advances in antiandrogen therapy, 20-40% of patients with metastatic CRPC demonstrate de novo resistance to the newly FDA-approved drugs abiraterone and enzalutamide, and the remaining patients acquire resistance during treatment (8) (9) (10) (11) . Several BET inhibitors have recently shown promising efficacy in preclinical models of CRPC (19) (20) (21) . Although the specific mechanisms behind this activity are a subject of intense scrutiny, BET inhibitors are thought to function partly by blocking BRD4 localization to AR target loci, thereby inhibiting In all experiments, tumors and plasma were harvested 8 h after the last dose for analysis (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). P values were determined using GraphPad Prism using an unpaired parametric t test with Welch's correction.
AR-mediated transcription (20) , and partly by abrogating c-MYC transcription (19) .
PROTACs, which are chimeric bifunctional small molecules that recruit an E3 ligase to force the destruction of a target protein of interest, have been developed by us and others as BET protein-targeting agents (23) (24) (25) . Until now, none of these BET PROTACs has been reported to have in vivo activity in a solidtumor malignancy. Moreover, the physicochemical properties of the first-generation BET PROTAC shown to be efficacious in a mouse model of AML necessitated intraperitoneal delivery, which usually is not a clinically relevant route of administration.
Here we have described a VHL-based BET targeting PROTAC, ARV-771, which shows <5 nM potency of BRD2/3/4 degradation in several prostate cancer cell lines. ARV-771 also has an antiproliferative effect that is up to 500-fold more potent than the BET inhibitors JQ-1 and OTX015 in these cell lines. Although we believe that ARV-771 and BET inhibitors share some common mechanism(s) of action, we hypothesize that protein depletion with a PROTAC could result in pleiotropic outcomes that would not be accessible with traditional inhibitors. Interestingly, it recently has been discovered that one of the mechanisms of acquired resistance to BET inhibitors in breast cancer involves completely BRD-independent transcriptional regulation mediated by BRD4 (39) . Similarly, in the same study, BRD4 knockdown by shRNA was shown to have much more significant antitumor effects than mere small-molecule inhibition. A separate study reported increased sensitivity of breast cancer lines to BRD4 siRNA compared with BET inhibition (40) . Given these emerging data, and because BET family proteins are known to have scaffolding functions whereby they interact with a variety of transcriptional regulators through their extraterminal and C-terminal domains (41, 42), we hypothesized that a BET degrader would have a more profound effect than a BET inhibitor on the growth and/or survival of prostate tumor cells. Our observation that ARV-771 lowers levels of FL-AR in addition to AR-V7 in VCaP cells, whereas BET inhibitors impact only the latter, supports this hypothesis. These data are consistent with other reports that show no impact of BET inhibitors on FL-AR levels (19, 20) , although one recent study claims that BET inhibitors do decrease FL-AR levels (22) . Accumulating evidence in the literature suggests that AR splice variants may mediate castration resistance, in part by heterodimerization with FL-AR and activation of the latter in an androgenindependent manner (15, 16, 37) . Although the attenuation of AR transcript variant levels is likely only one among many antiproliferative mechanisms downstream of the depletion of important epigenetic regulators such as BRD2/3/4, it nonetheless is of considerable importance in the context of PCa. The superiority of a BET PROTAC compared with a BET inhibitor is demonstrated by the observations that ARV-771 induces apoptosis in CRPC cells grown in vitro, whereas JQ-1 and OTX015 have only a cytostatic effect in the same time frame. Furthermore, ARV-771 induces regression of 22Rv1 xenografts compared with the 80% TGI that occurs in mice treated with OTX015. This effect clearly establishes the value of BET degraders over inhibitors, which, although efficacious in vivo, still result in progressive disease. Taken together, our results strongly support pursuing PROTAC-mediated BET degradation as a therapeutic strategy in CRPC.
Materials and Methods
All experiments described in this paper were approved by the Arvinas Senior Management Team. All human-derived materials used in this study were obtained from commercial vendors and did not require informed consent. For full methods, see SI Materials and Methods.
Reagents. The 22Rv1 and VCaP cell lines were purchased from ATCC. LnCap95 cells were a generous gift from Alan Meeker at The Johns Hopkins University School of Medicine. BRD2 (5848), BRD4 (13440), PARP (9532), and c-MYC (5605) antibodies were purchased from Cell Signaling Technology. BRD3 (sc-81202) antibody was purchased from Santa Cruz Biotechnology. Antibodies used for immunohistochemistry were c-MYC (ab32072, Abcam) and BRD4 (a301-985a50, Bethyl Laboratories). Actin and tubulin antibodies were purchased from Sigma.
Immunoblotting. Cells were lysed in RIPA buffer (catalog no. 89900, Thermo Fisher) supplemented with protease inhibitors (EDTA-free Protease Inhibitor Tablets, catalog no. 88266, Pierce). Lysates were centrifuged at 16,000 × g, and the supernatants were used for SDS/PAGE. Western blotting was carried out following standard protocols.
RT-qPCR. Cells were treated as indicated and were pelleted by centrifugation at 2,000 × g for 2 min, followed by washing with PBS. Total RNA was extracted using the Qiagen RNeasy Kit (catalog no. 74104), and cDNA was generated using the High-Capacity cDNA Reverse Transcription Kit (catalog no. 4368814, In all experiments, tumors and plasma were harvested 8 h after the last dose (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). P values were determined using GraphPad Prism using an unpaired parametric t test with Welch's correction.
